Stock Events

Bio-Techne 

$71.44
89
+$0.03+0.04% Friday 20:00

統計

當日最高
72.63
當日最低
70.62
52週最高
89.19
52週最低
51.42
成交量
564,539
平均成交量
1,115,682
市值
11.26B
市盈率
56.7
股息收益率
0.45%
股息
0.32

即將到來

股息

0.45%股息收益率
10年增長
0.24%
5年增長率
N/A
3年增長率
N/A
1年增長率
N/A

收益

1May確認
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0.4
0.48
0.55
0.63
預期每股收益
0.45
實際每股收益
0.48

人們還關注

此列表基於在 Stock Events 上關注 TECH 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

分析師評級

81.43$平均價格目標
最高估價為 $95。
來自過去 6 個月內的 7 個評級。這不是投資建議。
買入
57%
持有
43%
賣出
0%

關於

Health Technology
Biotechnology
Manufacturing
Biological Product (except Diagnostic) Manufacturing
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Show more...
首席執行官
Charles Kummeth
員工
3200
國家
US
ISIN
US09073M1045
WKN
000A12ENG

上市公司